Dear Friends of LRF, At the Lymphoma Research Foundation, our sights have always beenfixed to the horizon, looking ahead toward our vision of a world withoutlymphoma. Our focus on the future is why we have funded over $80Min lymphoma and…
On May 30, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received two or more prior lines of…
Lymphoma Research Foundation Funds 28 New Grants Supporting the Next Generation of Lymphoma Scientists New York, NY (May 20, 2024) – The Lymphoma Research Foundation (LRF), the nation’s largest nonprofit organization devoted to funding innovative lymphoma research and serving the…
On May 15, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic…
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two…
Celebrating the Original ‘Chemo Diva’ Upon receiving a lymphoma diagnosis, it’s not uncommon to search for others like you who are going through a similar experience. That sense of community and support, of seeing your own story reflected to you,…
Where Are They Now? Ryan Lynch, MD Dr. Ryan Lynch is a hematologist-oncologist at Fred Hutchinson Cancer Center. When did you become interested in the study of medicine? In lymphoma specifically? I had a great opportunity while I was in…